Compare Newmont Corporation (NEM) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs GeneDx Holdings Corp — how do they compare? Newmont Corporation trades at $127.77 (market cap $133.91B), while GeneDx Holdings Corp trades at $86.53 (market cap $2.56B). The key difference: Newmont Corporation is far larger — about 52.3× GeneDx Holdings Corp's market cap, and Newmont Corporation pays a 0.82% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| NEM | WGS | |
|---|---|---|
Market Cap | $133.91B | $2.56B |
Sector | Basic Materials | Technology |
52-Week High | $135.14 | $167.51 |
52-Week Low | $78.32 | $34.51 |
Enterprise Value | $130.50B | $2.60B |
Dividend Yield | 0.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NEM trades at $127.09, down 0.78% on the day, with a bullish technical signal and strong fundamental momentum. Revenue grew to $22.67B in 2025, with net income surging to $7.09B, and Q2 2026 EPS beat expectations at $2.10. Analyst consensus is strongly bullish with a $134.63 price target, supported by record free cash flow and institutional buying.
Outlook remains positive given earnings beats and gold's safe-haven appeal, but production challenges and cost pressures pose risks. The stock offers growth from operational strength and shareholder returns, yet investors face volatility from commodity prices and execution hurdles.
WGS trades at $85.87, down 0.14% today, with a bullish technical signal from moving averages and support at $84. The company reported Q2 2026 revenue of $114.4M, beating estimates, and returned to adjusted profitability early. However, net income remains negative at -$106M for 2026, with high valuation multiples like EV/EBITDA of 161.17. Recent news highlights partnerships and product launches, such as the NPC GenomeComplete initiative with Beren Therapeutics.
Outlook is mixed: strong analyst buy consensus (90.9%) and institutional interest support upside, but profitability challenges and a class action lawsuit pose risks. Revenue growth and operational improvements are key catalysts, yet high debt-to-asset ratios and negative margins require monitoring for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
